To determine in vivo anti-tumor efficacy we tested the EGFR (n=4), HER2 (n=4), and mesothelin (n=3) T-BsAbs in an intraperitoneal model of DSRCT (JN-DSRCT-1-luc), which more closely recapitulates human disease than a standard flank xenograft. This evidence concerns the gene ERBB2 and neoplasm.